Meeting
2017 ASCO Annual Meeting
First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
Authors
Debashis Sarker
King's College London, London, United Kingdom
Debashis Sarker , Elizabeth R. Plummer , Bristi Basu , Tim Meyer , Kai-Wen Huang , T.R. Jeffry Evans , Duncan Spalding , Yuk Ting Ma , Daniel H. Palmer , Cheng Ean Chee , Han Chong Toh , Nagy A Habib
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02716012
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2612)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2612
Abstract #
TPS2612
Poster Bd #
96a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
First Author: Debashis Sarker
Poster
2017 Gastrointestinal Cancers Symposium
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
First Author: Robin Kate Kelley
Poster
2011 ASCO Annual Meeting
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: R. S. Finn
Poster
2011 ASCO Annual Meeting
A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors.
First Author: L. E. Strong